ALK B ALK-ABELLO A/S

ITULATEK® approved for treatment of children and adolescents in Canada

ITULATEK® approved for treatment of children and adolescents in Canada

ALK (ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK’s regulatory filing for ITULATEK® (tree pollen sublingual allergy immunotherapy tablet) for treatment of children and adolescents aged five to 17. Accordingly, the tree pollen tablet is now indicated for treatment of moderate to severe seasonal allergic rhinitis, with or without conjunctivitis, induced by pollen from birch, alder, hazel, and/or oak, in children, adolescents, and adults five to 65 years of age in Canada.

Outside Europe, Canada is a key market for ALK’s respiratory tablet portfolio demonstrating solid double-digit growth. The extended ITULATEK® label is expected to further support market expansion in Canada.



Executive Vice President of R&D, Henriette Mersebach (MD), says: We appreciate the Canadian approval and look forward to offering this important treatment option to children and adolescents affected by uncontrolled tree pollen-induced respiratory allergy. The approval is yet another testament to our relentless pursuit of making our respiratory tablet portfolio available across markets and age groups".





ALK’s regulatory filing was based on data from the TT-06 clinical trial. TT-06 was a randomised, placebo-controlled Phase 3 trial involving 952 children and adolescents aged five to 17 with a clinical history of moderate to severe allergic rhinitis and/or conjunctivitis induced by pollen from birch trees and other trees in the birch homologous group. The trial confirmed that the treatment was well tolerated and had a favourable safety profile. The peer-reviewed results were published in 2024 in the European Journal of Allergy and Clinical Immunology.

The tree pollen tablet, branded ITULAZAX® in Europe and ITULATEK® in Canada, is currently approved by 22 countries for adult patients aged 18 to 65 and has recently been approved for treatment of children and adolescents aged five to 17 in 17 EU countries. Paediatric regulatory reviews are ongoing in Switzerland and the UK. These reviews are expected to complete in 2025.

With the extended label indications for ITULAZAX®/ITULATEK®, ALK has four tablets, covering 80% of the most prevalent respiratory allergies, approved for children, adolescents, and adults in Europe and Canada.

The approval does not affect ALK’s financial guidance for 2025.  

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Maiken Riise Andersen, tel.

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. ALK manufactures and markets allergy immunotherapy (‘AIT’) treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at .

Attachment



EN
08/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

 PRESS RELEASE

ALK presented comprehensive data on two new paediatric AIT tablets and...

ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025 At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which took place in Glasgow, Scotland, from 13 to 16 June 2025, the Danish pharmaceutical company ALK presented extensive data on anaphylaxis and paediatric allergy. During the EAACI 2025 scientific programme, ALK sponsored two major symposia and participated at several oral sessions, presenting data on the latest innovation in anaphylaxis, children with respiratory allergy, and recent advanc...

 PRESS RELEASE

ALK participates at Jefferies Global Healthcare Conference 2025 in New...

ALK participates at Jefferies Global Healthcare Conference 2025 in New York ALK (ALKB:DC / OMX: ALK B) today announced that the company is participating at the Jefferies Global Healthcare Conference 2025 in New York City taking place from 3 - 5 June 2025. Claus Steensen Sølje, Executive Vice President and CFO, this morning (EDT) participated in a fireside chat at the conference. A webcast replay of the fireside chat is available on ALK's investor site: or through this . ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. , mobile Media:...

 PRESS RELEASE

ITULATEK® approved for treatment of children and adolescents in Canada

ITULATEK® approved for treatment of children and adolescents in Canada ALK (ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK’s regulatory filing for ITULATEK® (tree pollen sublingual allergy immunotherapy tablet) for treatment of children and adolescents aged five to 17. Accordingly, the tree pollen tablet is now indicated for treatment of moderate to severe seasonal allergic rhinitis, with or without conjunctivitis, induced by pollen from birch, alder, hazel, and/or oak, in children, adolescents, and adults five to 65 years of age in Canada. Outside Europe, Can...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen

ResearchPool Subscriptions

Get the most out of your insights

Get in touch